Evaluation of the Idylla system for rapid detection of POLE mutations in colorectal and endometrial cancers
In brief
Rapid POLE test detects hotspot mutations with 96% sensitivity and 100% specificity
In a retrospective study of 40 colorectal and endometrial cancer samples, the automated test detected POLE hotspot mutations with 96% sensitivity and 100% specificity compared with next-generation sequencing. It could speed initial molecular screening, but reliable detection required adequate DNA and more than 20% tumor cells, so sequencing remains necessary for low-input or low-tumor samples.
- Journal
- Virchows Archiv : an international journal of pathology (Q1)
- Published
- 6 November 2026
- Study design
- Retrospective cohort
- Evidence level
- Level 3, Low (CEBM 3b)
- Authors
- Serena Barbe, Violaine Tran Quang, Caroline Saal, Julien Calderaro, Cécile Charpy, Jérémy Augustin, et al.
- PMID
- 42988877
- DOI
- 10.1007/s00428-026-04759-w
Why clinicians should know about it
- Picked for Pathology and Forensic Medicine (top studies of the week, 8 November 2026): Validates rapid molecular assay for tumour classification mutations
Abstract
Pathogenic exonuclease domain mutations in POLE define a hypermutated subtype of colorectal and endometrial cancers, with prognostic and therapeutic implications, particularly for immunotherapy. Detection currently relies on next-generation sequencing, which is sensitive but costly and time-consuming. The Idylla™ POLE-POLD1 Mutation Assay (Biocartis) is a fully automated real-time PCR for rapid detection of hotspot mutations, but its performance has not been fully evaluated.We retrospectively analyzed a cohort of 40 patients to evaluate the performance of the Idylla™ assay. All tumors underwent targeted NGS of POLE exons 9-14. DNA from formalin-fixed paraffin-embedded tissue was analyzed with the Idylla™ assay and results were compared with NGS. The assay's limit of detection was also determined.The Idylla™ assay detected POLE hotspot variants with 96% sensitivity and 100% specificity. Limit of detection experiments indicated reliable detection only in samples with DNA concentration > 5 ng/µL and tumor cell content > 20%.The Idylla™ POLE-POLD1 Mutation Assay enables rapid, robust detection of POLE hotspot variants in colorectal and endometrial cancers, with high concordance to NGS. Integrating Idylla as a front-line screening tool could accelerate molecular classification, though NGS remains necessary for samples with low tumor content or low DNA input.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.